Pancreatic Cancer Breakthrough: New Drug Daraxonrasib Nearly Doubles Survival Rate

TheTrendsWire acknowledges the deeply personal impact of pancreatic cancer on patients and families. This article reports on verified clinical trial data presented at a major medical conference and published in a peer-reviewed journal.

For decades, a diagnosis of advanced pancreatic cancer has meant one of the most devastating prognoses in all of oncology. Now, a new drug called daraxonrasib has achieved something scientists once thought impossible — cracking a genetic target that drives the vast majority of pancreatic tumours, and nearly doubling how long patients live.

The Scale of the Problem

Pancreatic cancer is the third-leading cause of cancer deaths in the United States, killing nearly 53,000 Americans every year. Around 67,000 people are expected to be diagnosed with the disease in the US in 2026. The five-year survival rate stands at just 13% — and for patients whose cancer has already spread to other organs, called metastatic disease, the five-year survival rate is approximately 3%.

Pancreatic cancer is so deadly in part because it rarely causes noticeable symptoms in its earliest stages, meaning it is most commonly diagnosed only after it has spread. For patients whose cancer has progressed despite chemotherapy, treatment options have historically been extremely limited.

That may now be changing.

The Drug — Daraxonrasib

Daraxonrasib is an experimental daily oral pill developed by Revolution Medicines. It targets the KRAS gene mutation — a mutation found in more than 90% of pancreatic cancers and one that drives uncontrolled tumour growth.

For decades, KRAS was considered "undruggable" by the oncology community. The protein's structure made it extremely difficult for conventional drug molecules to bind to and inhibit effectively. Revolution Medicines took a different approach. Rather than targeting KRAS directly, daraxonrasib attaches to a molecule called cyclophilin A inside cancer cells — a molecule that helps fold proteins into their final three-dimensional structures. This protein complex then binds to the active KRAS protein and shuts down its ability to signal cancer cells to multiply.

The result is a drug that achieves what no previous treatment could: effective suppression of the KRAS mutation that fuels most pancreatic cancers.

The Clinical Trial Results

The data come from the Phase 3 RASolute 302 clinical trial — a rigorous, randomised study involving 500 patients with metastatic pancreatic cancer who had received prior treatment. More than 91% of patients in the trial had a confirmed KRAS mutation.

The results were presented on May 31, 2026, by Dr Brian Wolpin of Dana-Farber Cancer Institute at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago — and simultaneously published in the New England Journal of Medicine, one of the most prestigious medical journals in the world.

The headline findings are striking:

• Daraxonrasib nearly doubled overall survival compared to standard chemotherapy — from 6.7 months to 13.2 months
• The drug reduced the risk of death for metastatic pancreatic cancer patients by 60%
• Daraxonrasib also nearly doubled progression-free survival compared to chemotherapy
• The drug produced fewer serious adverse events than standard chemotherapy

When Dr Wolpin presented these findings to the assembled oncologists and researchers in Chicago, he received a standing ovation — an extraordinarily rare response in the typically reserved world of clinical medicine.

"Game-changing" was the description used by multiple attending clinicians.

The Road to Approval

The FDA has already taken steps to accelerate access to daraxonrasib. On May 1, 2026, the FDA greenlit daraxonrasib for expanded access — meaning patients who cannot access the drug through clinical trials may now be able to obtain it through a compassionate use pathway.

The drug has also been selected for the FDA Commissioner's National Priority Voucher pilot programme, designed to accelerate the review of therapies aligned with US national health priorities. Revolution Medicines has formally announced its intention to submit the RASolute 302 data to the FDA and other global regulatory bodies — including the UK's MHRA — seeking full approval.

Full FDA approval, if granted, would make daraxonrasib the first KRAS inhibitor approved for pancreatic cancer — a historic milestone in oncology.

What This Means for Patients

It is essential to be precise about what these results do and do not mean for patients.

Daraxonrasib does not cure pancreatic cancer. The median overall survival of 13.2 months, while nearly double the 6.7 months seen with chemotherapy, still represents a deeply difficult prognosis. The drug currently applies specifically to patients with metastatic disease whose cancer has progressed after previous treatment — not all pancreatic cancer patients.

However, the significance of the result should not be understated. Doubling median survival in a cancer that has remained stubbornly resistant to treatment progress for decades is a genuine scientific achievement. And the 60% reduction in risk of death is statistically robust and clinically meaningful.

Oncologists expect further trials to explore combination therapies pairing daraxonrasib with other drugs to prevent tumours from developing resistance — the next frontier in building on this breakthrough.

"This milestone represents a likely shift in pancreatic cancer treatment," wrote Professor Christopher Lieu of the University of Colorado Anschutz Medical Campus, an oncologist who reviewed the findings. "Should daraxonrasib succeed, it could help set the stage for more precise, personalised and effective treatments for pancreatic cancer in the years to come."

Key Takeaways

• Daraxonrasib is a new daily oral pill that targets the KRAS mutation found in more than 90% of pancreatic cancers
• In a Phase 3 trial of 500 patients, it nearly doubled overall survival from 6.7 months to 13.2 months compared to chemotherapy
• The drug reduced the risk of death for metastatic pancreatic cancer patients by 60%
• Results presented at the 2026 ASCO Annual Meeting in Chicago and published in the New England Journal of Medicine
• Dr Brian Wolpin of Dana-Farber Cancer Institute received a standing ovation when presenting the findings
• The FDA approved expanded access on May 1, 2026 — full approval application underway
• The drug does not cure pancreatic cancer — it applies to patients with metastatic disease after prior treatment
• Pancreatic cancer kills approximately 53,000 Americans per year and is the third-leading cause of cancer death in the US